OncoZenge AB (SE:ONCOZ)

:ONCOZ

ONCOZ

OncoZenge AB

RESEARCH TOOLSreports

Want to see SE:ONCOZ full AI Analyst Report?

OncoZenge AB (ONCOZ) Price & Analysis

0 Followers

ONCOZ Stock Chart & Stats

kr5.51

kr0.40(6.64%)

At close: Mar 06 4:00 PM EST

kr5.51

kr0.40(6.64%)

Day’s Range― - ―

52-Week Rangekr4.52 - kr10.28

Previous CloseN/A

Volume9.67K

Average Volume (3M)35.93K

Market Cap

kr99.46M

Enterprise Valuekr106.06M

Total Cash (Recent Filing)kr3.71M

Total Debt (Recent Filing)kr7.50M

Price to Earnings (P/E)―

Beta1.18

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.20

Shares Outstanding14,048,068

10 Day Avg. Volume29,683

30 Day Avg. Volume35,930

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)-139.70

Price to Sales (P/S)30.78

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-1

Revenue Forecast (FY)kr10.00M

Bulls Say, Bears Say

Bulls Say

Focused Lead AssetOncoZenge’s sole clinical focus on BupiZenge targets a clear, durable unmet need—localized oral mucositis pain in cancer patients. A specialized buccal formulation can deliver clinical differentiation and streamlined development/commercial focus, aiding regulatory clarity and partner interest over months.

Multiple Commercialization PathwaysThe company’s articulated monetization routes (direct sales, licensing, upfront and milestone payments, royalties) provide strategic flexibility. These durable options let management pursue partnerships to fund development, reduce execution risk and accelerate commercialization without sole reliance on product sales.

Improving Loss TrajectoryA reduction in reported losses versus 2022 suggests operating cost control or progress reducing burn intensity. If sustained, this structural improvement supports a longer runway and better negotiating leverage with partners or funders, improving funding prospects over the coming months.

Bears Say

Weakened Balance SheetNegative equity and freshly introduced debt materially reduce financial flexibility and raise solvency risk. Over a multi-month horizon this structural weakening increases likelihood of requiring dilutive equity or restrictive financing, complicating long-term R&D and commercialization plans.

Persistent Cash BurnSustained negative operating cash flow (~-SEK 13.1m) signals continued reliance on external financing to fund operations. This enduring cash burn constrains strategic options, risks interruption of development activities without timely funding, and increases fundraising dilution or debt costs.

Small, Volatile Revenue & Deep LossesVery limited, inconsistent revenue coupled with substantial operating/net losses means the business generates no reliable internal cash to fund growth. Structurally, this keeps OncoZenge in a pre-commercial risk profile where sustained operations depend on external capital or partner deals.

ONCOZ FAQ

What was OncoZenge AB’s price range in the past 12 months?

OncoZenge AB lowest stock price was kr4.51 and its highest was kr10.28 in the past 12 months.

What is OncoZenge AB’s market cap?

OncoZenge AB’s market cap is kr99.46M.

When is OncoZenge AB’s upcoming earnings report date?

OncoZenge AB’s upcoming earnings report date is Aug 27, 2026 which is in 95 days.

How were OncoZenge AB’s earnings last quarter?

Currently, no data Available

Is OncoZenge AB overvalued?

According to Wall Street analysts OncoZenge AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoZenge AB pay dividends?

OncoZenge AB does not currently pay dividends.

What is OncoZenge AB’s EPS estimate?

OncoZenge AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoZenge AB have?

OncoZenge AB has 14,048,068 shares outstanding.

What happened to OncoZenge AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of OncoZenge AB?

Currently, no hedge funds are holding shares in SE:ONCOZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoZenge AB

OncoZenge AB is a Swedish pharmaceutical company focused on the development and commercialization of innovative treatments for cancer. Leveraging advanced research in oncology, the company aims to address unmet medical needs by offering novel therapeutic solutions that improve patient outcomes. OncoZenge operates within the biotechnology and pharmaceutical sectors, concentrating on the development of proprietary drug formulations and delivery systems designed to enhance the efficacy and safety of cancer therapies.